Compare · MBIO vs NVO
MBIO vs NVO
Side-by-side comparison of Mustang Bio Inc. (MBIO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBIO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 37572.2x MBIO ($5.0M).
- Over the past year, MBIO is down 44.3% and NVO is down 41.7% - NVO leads by 2.6 points.
- NVO has hit the wire 11 times in the past 4 weeks while MBIO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for MBIO).
- Company
- Mustang Bio Inc.
- Novo Nordisk A/S
- Price
- $0.71-9.36%
- $42.01-2.10%
- Market cap
- $5.0M
- $187.53B
- 1M return
- -5.43%
- -5.38%
- 1Y return
- -44.31%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 1
- 25
Mustang Bio Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MBIO
- SEC Form 10-Q filed by Mustang Bio Inc.
- President, CEO and Interim CFO Litchman Manuel Md covered exercise/tax liability with 19 shares, decreasing direct ownership by 1% to 1,615 units (SEC Form 4)
- Mustang Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-K filed by Mustang Bio Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Mustang Bio Inc.
- Large owner Fortress Biotech, Inc. was granted 278,385 shares, increasing direct ownership by 108% to 536,577 units (SEC Form 4)
- Director Herskowitz Neil sold $238 worth of shares (247 units at $0.96), decreasing direct ownership by 63% to 145 units (SEC Form 4)
- Director Chill Adam J. sold $4 worth of shares (4 units at $0.95), decreasing direct ownership by 1% to 375 units (SEC Form 4)
- Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)
- Mustang Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates